Related Experiment Video

Updated: May 5, 2026

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

6.9K

Translating molecular discoveries into new therapies for atherosclerosis

Daniel J Rader1, Alan Daugherty

  • 1Cardiovascular Institute and Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, 654 BRBII/III, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, USA. rader@mail.med.upenn.edu

Nature
|February 22, 2008
PubMed

Insights

Atherosclerosis, arterial wall thickening, causes major diseases. Targeting lipoproteins and the renin-angiotensin-aldosterone system shows therapeutic benefits for atherosclerotic cardiovascular disease.

Area of Science:

  • Cardiovascular Science
  • Pathology
  • Medical Research

Background:

  • Atherosclerosis, characterized by arterial wall thickening, is a primary cause of global mortality from coronary artery and cerebrovascular diseases.
  • Lipoproteins and the renin-angiotensin-aldosterone system are implicated in atherosclerotic cardiovascular disease pathogenesis.
  • Understanding risk factors like hypertension, dyslipidemia, and diabetes is crucial for managing atherosclerosis.

Purpose of the Study:

  • To review the role of lipoproteins and the renin-angiotensin-aldosterone system in atherosclerosis.
  • To explore the contribution of major risk factors to atherosclerotic disease.
  • To identify novel therapeutic targets based on molecular pathogenesis.

Main Methods:

  • Literature review of clinical trials and research studies.
  • Analysis of the impact of lipoproteins and the renin-angiotensin-aldosterone system.
  • Examination of the molecular mechanisms underlying atherosclerotic plaque development.

Main Results:

  • Clinical trials confirm the benefit of targeting specific lipoproteins.
  • Interventions targeting the renin-angiotensin-aldosterone system demonstrate efficacy.
  • Research is uncovering new therapeutic targets by elucidating molecular pathogenesis.

Conclusions:

  • Targeting lipoproteins and the renin-angiotensin-aldosterone system offers a promising therapeutic strategy for atherosclerotic cardiovascular disease.
  • Further research into the molecular basis of atherosclerosis and risk factor contributions will yield new treatment avenues.

More Related Videos

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

7.7K
Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients09:09

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

221

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741